|
May 29
|
ASCO 2025: Merus wins in head-to-head with Bicara for head and neck cancer
|
|
May 25
|
BofA Maintains Buy Rating on Merus (MRUS), Lifts PT
|
|
May 25
|
Merus (MRUS) Price Target Raised at BMO After Positive Phase 2 Data
|
|
May 23
|
Merus updates on Petosemtamab+Pembrolizumab data in HNSCC
|
|
May 23
|
Update: Merus Shares Surge After Revealing Favorable Interim Cancer Trial Data
|
|
May 23
|
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics
|
|
May 23
|
Merus Says Interim Cancer Trial Data Show 'Robust' Efficacy, Durability; Shares Jump Premarket
|
|
May 22
|
Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
|
|
May 10
|
Merus First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
|
|
May 9
|
Merus N.V. (MRUS): Among the Best Cancer Stocks to Invest in for Long-Term Gain
|
|
May 8
|
Merus to Present at BofA Securities 2025 Health Care Conference
|
|
May 7
|
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 7
|
Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update
|
|
May 7
|
Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to Decline
|
|
Apr 18
|
Is Merus (NASDAQ:MRUS) the Best High Short Interest Stock to Buy Now?
|
|
Apr 10
|
Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength?
|
|
Feb 25
|
Merus to Present at Upcoming Investor Conferences
|
|
Feb 20
|
Will Iovance Biotherapeutics (IOVA) Report Negative Earnings Next Week? What You Should Know
|
|
Feb 18
|
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
|
|
Feb 13
|
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit
|